VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis

Abstract

BackgroundAngiogenesis appears to be a first-order event in psoriatic arthritis (PsA). Among angiogenic factors, the cytokines vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factors 1 and 2 (FGF1 and FGF2) play a central role in the initiation of angiogenesis. Most of these cytokines have been shown to be upregulated in or associated with psoriasis, rheumatoid arthritis (RA) or ankylosing spondylitis (AS). As these diseases share common susceptibility associations with PsA, investigation of these angiogenic factors is warranted.MethodsTwo hundred and fifty-eight patients with PsA and 154 ethnically matched controls were genotyped using a Sequenom chip-based MALDI-TOF mass spectrometry platform. Four SNPs in the VEGF gene, three SNPs in the EGF gene and one SNP each in FGF1 and FGF2 genes were evaluated. Statistical analysis was performed using Fisher's exact test, and the Cochrane-Armitage trend test. Associations with haplotypes were estimated by using weighted logistic models, where the individual haplotype estimates were obtained using Phase v2.1.ResultsWe have observed an increased frequency in the T allele of VEGF +936 (rs3025039) in control subjects when compared to our PsA patients [Fisher's exact p-value = 0.042; OR 0.653 (95% CI: 0.434, 0.982)]. Haplotyping of markers revealed no significant associations.ConclusionThe T allele of VEGF in +936 may act as a protective allele in the development of PsA. Further studies regarding the role of pro-angiogenic markers in PsA are warranted.

Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population

“…The gene is highly polymorphic, and several single nucleotide polymorphisms (SNPs) have been associated with altered gene expression and higher VEGF plasma levels (3-7). In addition, previous studies have revealed a correlation with cancer development and progression (8)(9)(10)(11), as well as with Behcet's disease, adult respiratory distress syndrome, rheumatoid arthritis and psoriatic arthritis (12)(13)(14)(15).…”

Vascular endothelial growth factor gene polymorphisms and psoriasis susceptibility: a meta-analysis

“…Ten studies were identified by electronic and manual searching and all 10 were selected for full-text review based on title and abstract details (Young et al, 2004(Young et al, , 2006Barile et al, 2006;Butt et al, 2007;Lee et al, 2008;Stefanaki et al, 2008;Wang et al, 2008;Wongpiyabovorn et al, 2008;Wu et al, 2010;Zablotna et al, 2013). However, 3 of the 10 were excluded because they had no control group or did not contain genotype data (Young et al, 2006;Lee et al, 2008;Stefanaki et al, 2008).…”

“…However, 3 of the 10 were excluded because they had no control group or did not contain genotype data (Young et al, 2006;Lee et al, 2008;Stefanaki et al, 2008). Thus, 7 studies met the study inclusion criteria, and these studies included a total 1956 subjects (psoriasis 665, controls 1291) and consisted of European and Asian populations (Young et al, 2004;Barile et al, 2006;Butt et al, 2007;Wang et al, 2008;Wongpiyabovorn et al, 2008;Wu et al, 2010;Zablotna et al, 2013) (Table 1).…”

“…Particularly, the +405 C/G polymorphism in the 5'-untranslated region and 3 polymorphisms in the promoter region (-460 C/T, -1154 A/G, and -2578 A/C) have been associated with VEGF production (Young et al, 2006). Previous studies showed that these polymorphisms are associated with several autoimmune diseases, including psoriasis, while other reports found no such associations (Young et al, 2004;Barile et al, 2006;Butt et al, 2007;Wang et al, 2008;Wongpiyabovorn et al, 2008;Wu et al, 2010;Zablotna et al, 2013). The reasons for these disparities may be small sample sizes, low statistical power, and/or clinical heterogeneity.…”

Perfil de citocinas angiogênicas séricas em pacientes com dermatomiosite

“…Níveis aumentados, tanto no soro quanto na sinóvia, já foram relatados em pacientes com artrite reumatoide, relacionando o aumento com a doença inicial e maior destruição sinovial (Ishikawa et al, 2011 (Butt et al, 2006;Thomas et al, 2000) e no sangue de pacientes com esclerose sistêmica e DM (Kadono et al, 1996).…”